Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

HC Wainwright & Co. Initiates Coverage On Soleno Therapeutics with Buy Rating, Announces Price Target of $70

Author: Benzinga Newsdesk | September 03, 2024 07:49am
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Buy rating and announces Price Target of $70.

Posted In: SLNO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist